- Home
- ORMP vs ASMB Comparison
ORMP vs ASMB Comparison
Compare ORMP & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORMP
- ASMB
- Stock Information
- Founded
- ORMP 2002
- ASMB 2005
- Country
- ORMP United States
- ASMB United States
- Employees
- ORMP N/A
- ASMB N/A
- Industry
- ORMP Biotechnology: Pharmaceutical Preparations
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- ORMP Health Care
- ASMB Health Care
- Exchange
- ORMP Nasdaq
- ASMB Nasdaq
- Market Cap
- ORMP N/A
- ASMB 139.8M
- IPO Year
- ORMP N/A
- ASMB 2010
- Fundamental
- Price
- ORMP $2.15
- ASMB $18.75
- Analyst Decision
- ORMP Hold
- ASMB Strong Buy
- Analyst Count
- ORMP 1
- ASMB 3
- Target Price
- ORMP N/A
- ASMB $33.00
- AVG Volume (30 Days)
- ORMP 63.0K
- ASMB 43.5K
- Earning Date
- ORMP 08-15-2025
- ASMB 08-07-2025
- Dividend Yield
- ORMP N/A
- ASMB N/A
- EPS Growth
- ORMP N/A
- ASMB N/A
- EPS
- ORMP N/A
- ASMB N/A
- Revenue
- ORMP $2,000,000.00
- ASMB $32,154,000.00
- Revenue This Year
- ORMP N/A
- ASMB $0.04
- Revenue Next Year
- ORMP N/A
- ASMB N/A
- P/E Ratio
- ORMP N/A
- ASMB N/A
- Revenue Growth
- ORMP 196.74
- ASMB 148.33
- 52 Week Low
- ORMP $1.82
- ASMB $7.75
- 52 Week High
- ORMP $3.09
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- ORMP 46.79
- ASMB 65.84
- Support Level
- ORMP $2.09
- ASMB $18.01
- Resistance Level
- ORMP $2.20
- ASMB $18.99
- Average True Range (ATR)
- ORMP 0.09
- ASMB 0.84
- MACD
- ORMP -0.00
- ASMB -0.05
- Stochastic Oscillator
- ORMP 36.84
- ASMB 84.42
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.